Duration of Antibiotic Therapy in Acute Kidney Graft Pyelonephritis (AGPN): Effect on the Risk of Recurrence

DUTRAPYL STUDY : Duration of Antibiotic Therapy in Acute Kidney Graft Pyelonephritis: Effect on the Risk of Recurrence

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06848816

Acronym

DUTRAPYL

Enrollment

500

Registered

2025-02-27

Start date

2020-01-01

Completion date

2025-12-31

Last updated

2025-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Transplantation Recipients, Pyelonephritis Acute

Keywords

Acute graft pyelonephritis, duration treatment, antibiotic, recurrence, relapse

Brief summary

The aim of this study is to evaluate the impact of the duration of antibiotic therapy on the risk of recurrence in kidney graft pyelonephritis. The secondary objectives are to identify the factors associated with the duration of antibiotic therapy in acute kidney graft pyelonephritis, identify the factors associated with recurrence of acute kidney graft pyelonephritis within 3 months, evaluate the impact of the duration of antibiotic therapy on antibiotic-related complications and assess the impact of the duration of antibiotic therapy on the progression of renal function after acute kidney graft pyelonephritis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients * Kidney transplant recipients with a functional graft. * Hospitalization with acute pyelonephritis (APN) defined by fever OR chills (noted in the clinical records) AND bacteriuria AND exclusion of another obvious cause of fever. (For rehospitalizations, also include cases where antibiotic therapy was initiated based on suspicion, even in the absence of documented infection.)

Exclusion criteria

* Age \< 18 years. * Vacationing patient or lost to follow-up with follow-up \< 3 months.

Design outcomes

Primary

Measure	Time frame	Description
Relaspe AGPN	3 month	Rehospitalization for acute kidney graft pyelonephritis (AGPN) within three months after completion of treatment

Secondary

Measure	Time frame	Description
ITU relapse	3 month	Antibiotic treatment for urinary tract infection within 3 months after completion of treatment.
Identical microorganism relapsing AGPN	3 month	New episode of AGPN with the same pathogen within 3 months after completion of treatment
Multidrug resistant emerging pathogens	3 month	Infection with a multidrug-resistant bacteria within 3 months after completion of treatment
Early AGPN relapse	1 month	Rehospitalization for acute kidney graft pyelonephritis (AGPN) within one month after completion of treatment
Early kidney function evolution	1 month	Evolution of renal function (creatininemia) 1 month after completion of treatment for APNAG.
3 month kidney function evolution	3 month and 21 days	Evolution of renal function (creatininemia) 3 +/- 21 days after completion of treatment for AGPN
Risk factors	3 month	Clinical and biological Factors associated with AGPN recurrence independently of the duration of antibiotic therapy
Clostridioides difficile colitis	3 month	Occurrence of Clostridioides difficile colitis within 3 months after completion of treatment

Countries

France

Outcome results